KalVista Pharmaceuticals Inc

KalVista insider buys: CDO Yea Christopher’s RSU‑triggered purchase of 1,774 shares signals confidence amid EKTERLY data hype, offering a cautious buy hint for investors.

CEO’s insider RSU buy at KalVista signals long‑term confidence as EKTERLY data rises, hinting a potential biotech turnaround for value‑oriented investors.

KalVista CEO’s new share purchase signals confidence in the company’s EKTERLY pipeline and could hint at future upside for investors.